http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
-
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
-
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
-
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical
-
Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
-
Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
-
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
-
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
-
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
-
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
-
Corbus Pharma (CRBP) Appoints Dr. Dominic Smethurst as Chief Medical Officer
-
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
-
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Corbus Pharma (CRBP) Reports CRB-701 Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors
-
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented
-
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
-
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
-
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
-
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
-
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
-
Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
-
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
-
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on its Anti-aVb8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
-
Corbus Pharmaceuticals to Present Pre-Clinical Data Characterizing its CRB-701 Nectin-4 ADC at the at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference
-
Corbus Pharmaceuticals Set to Join Russell Microcap® Index
-
Corbus Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference
-
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals to Present Latest Pre-Clinical Data on CRB-601 avβ8 Blocking Antibody at the New York Academy of Sciences' Frontiers in Cancer Immunotherapy Meeting
-
Corbus Pharmaceuticals Hosting Virtual 'Meet the Expert' Series: Blocking TGFβ with CRB-601--a New Play for an Old Target
-
Corbus Pharma (CRBP) Presents Latest Pre-Clinical Data on CRB-601
-
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting
-
Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting
-
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
-
Corbus Pharma (CRBP) Appoints Yong Ben to its Board
-
Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA
-
Corbus Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
-
Corbus Pharma (CRBP) Adds Clinical Stage Nectin-4 targeting Antibody Drug Conjugate
-
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)
-
Corbus Pharma (CRBP) Presents Latest Preclinical Data for CRB-601
-
Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
-
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
-
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors
-
Corbus Pharma (CRBP) Presents First Pre-Clinical Data for CRB-913
